CTCL Resources

Helpful resources for healthcare professionals and patients to learn more about ISTODAX and CTCL

ISTODAX Brochure

ISTODAX Brochure

An in-depth resource that highlights the efficacy and safety information from ISTODAX clinical trials and important ISTODAX dosing information

Dosing Guide for Nurses and Pharmacists

Dosing Guide for Nurses and Pharmacists

A helpful resource, including guidelines for dose modification with ISTODAX and instructions for how to reconstitute and prepare ISTODAX for administration

 

My Treatment with ISTODAX Patient Guide

My Treatment with ISTODAX Patient Guide

Important information for patients about their condition and what to expect from treatment with ISTODAX

The organizations below can help patients access more information about their condition, as well as provide them with additional resources and support.

Listing of these resources does not constitute endorsement by Celgene Corporation of an organization or its communications.

Lymphoma of the Skin

http://www.cancer.org/cancer/lymphomaoftheskin/index
(800-227-2345)

Cancer Care®

Cutaneous T-cell Lymphoma
http://www.cancercare.org/diagnosis/cutaneous_t-cell_lymphoma
(800-813-HOPE) (800-813-4673)

ClinicalTrials.gov

www.clinicaltrials.gov
(online only)

Cutaneous Lymphoma Foundation

http://www.clfoundation.org
(248-644-9014)

Leukemia & Lymphoma Society®

Non-Hodgkin Lymphoma
http://www.lls.org/diseaseinformation/lymphoma/nonhodgkinlymphoma

CTCL Facts

http://www.lls.org/resourcecenter/freeeducationmaterials/lymphoma/cutaneoustcell
(800-955-4572)

Lymphoma Research Foundation

Cutaneous T-cell Lymphoma
http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6300151
(800-500-9976)

National Cancer Institute

Mycosis Fungoides and Sézary Syndrome Treatment
http://www.cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/Patient
(800-4-CANCER) (800-422-6237)


Check back for updates as new resources
become available.

NEXT: PATIENT SUPPORT INFORMATION

Important Safety Information

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Cutaneous T-Cell Lymphoma
The most common Grade 3/4 adverse reactions (>5%) regardless of causality in Study 1 (N=102) were infections (11%) and asthenia/fatigue (8%), and in Study 2 (N=83) were lymphopenia (37%), infections (33%), neutropenia (27%), leukopenia (22%), anemia (16%), asthenia/fatigue (14%), thrombocytopenia (14%), hypophosphatemia (10%), vomiting (10%), dermatitis/exfoliative dermatitis (8%), hypermagnesemia (8%), hyperuricemia (8%), hypocalcemia (6%), nausea (6%), and pruritus (6%).

Infections were the most common type of serious adverse event reported in both Study 1 (N=102) and Study 2 (N=83) with 8 patients (8%) in Study 1 and 26 patients (31%) in Study 2 experiencing a serious infection.

The most common adverse reactions regardless of causality in Study 1 (N=102) were nausea (56%), asthenia/fatigue (53%), infections (46%), vomiting (34%), and anorexia (23%), and in Study 2 (N=83) were nausea (86%), asthenia/fatigue (77%), anemia (72%), thrombocytopenia (65%), ECG ST-T wave changes (63%), neutropenia (57%), lymphopenia (57%), infections (54%), anorexia (54%), vomiting (52%), hypocalcemia (52%), hyperglycemia (51%), hypoalbuminemia (48%), leukopenia (46%), dysgeusia (40%), and constipation (39%).

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

Please click here for Full Prescribing Information.

get flash
TO BEGIN: Select and drag a manifestation to the appropriate area on the body.
get flash
get flash